OPTIMIZING CROSSOVER FROM TICAGRELOR TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME: THE CAPITAL OPTI-CROSS RANDOMIZED TRIAL

Secondary outcomes included PRUs at each time point, proportion of patients with high on treatment platelet reactivity (HTPR, PRU>208), and major adverse cardiac events (MACE) defined as cardiovascular mortality, re-infarction, urgent revascularization and stroke were evaluated at 30-days.

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2015-03, Vol.65 (10), p.A108-A108
Main Authors: Pourdjabbar, Ali, Hibbert, Benjamin, Simard, Trevor, Ramirez, F Daniel, Lugomirski, Peter, Maze, Ronnen, Labinaz, Marino, Chong, Aun-Yeong, Dick, Alexander, Glover, Chris, Froeschl, Michael, Marquis, Jean-Francois, Wells, George, Le May, Michel, So, Derek
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Cardiology
Cardiovascular
Drug therapy
Internal Medicine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Secondary outcomes included PRUs at each time point, proportion of patients with high on treatment platelet reactivity (HTPR, PRU>208), and major adverse cardiac events (MACE) defined as cardiovascular mortality, re-infarction, urgent revascularization and stroke were evaluated at 30-days.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(15)60108-5